Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$941.0m

Sana Biotechnology Past Earnings Performance

Past criteria checks 0/6

Sana Biotechnology's earnings have been declining at an average annual rate of -3.2%, while the Biotechs industry saw earnings growing at 19.7% annually.

Key information

-3.2%

Earnings growth rate

82.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-72.1%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

Revenue & Expenses Breakdown

How Sana Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SANA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-24573223
31 Mar 240-30973281
31 Dec 230-28373254
30 Sep 230-27676246
30 Jun 230-36263284
31 Mar 230-32061248
31 Dec 220-26958204
30 Sep 220-30056232
30 Jun 220-29854232
31 Mar 220-20753135
31 Dec 210-35650275
30 Sep 210-35847266
30 Jun 210-32741230
31 Mar 210-43334336
31 Dec 200-28528232
30 Sep 200-21525174
31 Dec 190-13122102

Quality Earnings: SANA is currently unprofitable.

Growing Profit Margin: SANA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SANA is unprofitable, and losses have increased over the past 5 years at a rate of 3.2% per year.

Accelerating Growth: Unable to compare SANA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SANA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: SANA has a negative Return on Equity (-72.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies